0.55
+0.0171(+3.21%)
Currency In USD
| Previous Close | 0.53 |
| Open | 0.54 |
| Day High | 0.55 |
| Day Low | 0.51 |
| 52-Week High | 17.83 |
| 52-Week Low | 0.46 |
| Volume | 311,804 |
| Average Volume | 800,703 |
| Market Cap | 29.37M |
| PE | -0.21 |
| EPS | -2.58 |
| Moving Average 50 Days | 0.72 |
| Moving Average 200 Days | 1.71 |
| Change | 0.02 |
If you invested $1000 in ALX Oncology Holdings Inc. (ALXO) since IPO date, it would be worth $18.33 as of May 06, 2025 at a share price of $0.55. Whereas If you bought $1000 worth of ALX Oncology Holdings Inc. (ALXO) shares 3 years ago, it would be worth $52.33 as of May 06, 2025 at a share price of $0.55.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025
GlobeNewswire Inc.
May 02, 2025 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and
ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma
GlobeNewswire Inc.
Apr 25, 2025 5:10 PM GMT
- Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology’s investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R2) was well-tolerated and demonstrated promising anti-tumor activity - Combinatio
ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints
GlobeNewswire Inc.
Apr 25, 2025 1:00 PM GMT
In ASPEN-03 and ASPEN-04 trials, efficacy data do not support advancing evorpacept in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), into a registrational studyCompany remains confident in continuing to pursue evorpacept in mu